𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Long-term efficacy and safety of mycophenolate mofetil in liver transplant recipients with calcineurin inhibitor-induced renal dysfunction

✍ Scribed by Robert O. Koch; Ivo W. Graziadei; Frank Schulz; Karin Nachbaur; Alfred Königsrainer; Raimund Margreiter; Wolfgang Vogel

Publisher
Springer
Year
2004
Tongue
English
Weight
234 KB
Volume
17
Category
Article
ISSN
0934-0874

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Mycophenolate mofetil in combination wit
Mycophenolate mofetil in combination with reduction of calcineurin inhibitors for chronic renal dysfunction after liver transplantation
✍ Georges-Philippe Pageaux; Lionel Rostaing; Yvon Calmus; Christophe Duvoux; Clair 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB 👁 1 views

The purpose of the study was to introduce mycophenolate mofetil (MMF) in liver transplant recipients with renal dysfunction to decrease calcineurin inhibitor (CNI) dosages without increasing rejection risk. In this prospective, multicenter, randomized study, chronic CNI-related renal dysfunction was

Long-term effects of calcineurin inhibit
Long-term effects of calcineurin inhibitor conversion to mycophenolate mofetil on renal function after liver transplantation
✍ Caroline Créput; Frederique Blandin; Benjamin Deroure; Bruno Roche; Faouzi Salib 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 123 KB 👁 1 views

Calcineurin inhibitors (CNIs) are the cornerstone of immunosuppression after liver transplantation. However, CNI treatment is frequently associated with chronic renal failure (CRF). The reduction or interruption of CNI may reduce renal failure. We prospectively studied 49 liver recipients treated wi

Long-term renal function in liver transp
Long-term renal function in liver transplant recipients and impact of immunosuppressive regimens (calcineurin inhibitors alone or in combination with mycophenolate mofetil): The TRY study
✍ Svetlana Karie-Guigues; Nicolas Janus; Faouzi Saliba; Jerome Dumortier; Christop 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 152 KB 👁 1 views

The prevalence of renal insufficiency before and at 1, 12, and 60 months after liver transplantation (LTx; primary endpoint) and the changes in the glomerular filtration rate (GFR) at same time points according to the immunosuppressive regimen (coprimary endpoint) were investigated. The primary outc

Pharmacokinetics, efficacy, and safety o
Pharmacokinetics, efficacy, and safety of mycophenolate mofetil in combination with standard-dose or reduced-dose tacrolimus in liver transplant recipients
✍ Björn Nashan; Faouzi Saliba; Francois Durand; Rafael Barcéna; Jose Ignacio Herre 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 455 KB 👁 1 views

The pharmacokinetics of mycophenolate mofetil (MMF) in liver transplant recipients may change because of pharmacokinetic interactions with coadministered immunosuppressants or because changes in the enterohepatic anatomy may affect biotransformation of MMF to mycophenolic acid (MPA) and enterohepati

Sirolimus in liver transplant recipients
Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens
✍ Derek DuBay; Rob J. Smith; Kenneth G. Qiu; Gary A. Levy; Leslie Lilly; George Th 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 129 KB

The purpose of this study is to review the clinical experience with sirolimus immunosuppression in liver transplant patients with calcineurin inhibitor-induced chronic renal insufficiency. The study design is a case-control retrospective series. Fifty-seven liver transplant patients with renal insuf

Long-term outcome of mycophenolate mofet
Long-term outcome of mycophenolate mofetil rescue therapy for resistant acute allograft rejection in pediatric liver transplant recipients
✍ Marion Margaret Aw; Anita Verma; Mohamed Rela; Nigel Heaton; Giorgina Mieli-Verg 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB 👁 1 views

Mycophenolate mofetil (MMF) has been used to rescue liver allografts with steroid-resistant rejection (SRR). However, the long-term outcome of these patients is not known. This study evaluates the long-term outcome of MMF rescue therapy for SRR in pediatric liver allograft recipients. Twenty-six chi